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RESEARCH ARTICLE
Extracellular microRNAs in blood differentiate between ischaemic and
haemorrhagic stroke subtypes
M. Yashar S. Kalania‡*, Eric Alsopb*, Bessie Meechoovetb, Taylor Beecroftb, Komal Agrawalb,
Timothy G. Whitsettc, Matthew J. Huentelmanb, Robert F. Spetzlerd, Peter Nakajie, Seungchan Kimf
and Kendall Van Keuren-Jensenb
aDepartments of Neurological Surgery and Neuroscience, University of Virginia School of Medicine, Charlottesville, VA, USA; bDivision of
Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA; cThe Translational Genomics Research Institute, Phoenix,
AZ, USA; dDepartment of Neurological Surgery, Barrow Neurological Institute, Phoenix, AZ, USA; eDepartment of Neurosurgery, Banner
Heath and University of Arizona College of Medicine, Phoenix, AZ, USA; fCenter for Computational Systems Biology, Department of Electrical
and Computer Engineering, Roy G. Perry College of Engineering, Prairie View A & M University, Prairie View, TX, USA
ABSTRACT
Rapid identification of patients suffering from cerebral ischaemia, while excluding intracerebral
haemorrhage, can assist with patient triage and expand patient access to chemical and mechan-
ical revascularization. We sought to identify blood-based, extracellular microRNAs 15 (ex-miRNAs)
derived from extracellular vesicles associated with major stroke subtypes using clinical samples
from subjects with spontaneous intraparenchymal haemorrhage (IPH), aneurysmal subarachnoid
haemorrhage (SAH) and ischaemic stroke due to cerebral vessel occlusion. We collected blood
from patients presenting with IPH (n = 19), SAH (n = 17) and ischaemic stroke (n = 21). We
isolated extracellular vesicles from plasma, extracted RNA cargo, 20 sequenced the small RNAs
and performed bioinformatic analyses to identify ex-miRNA biomarkers predictive of the stroke
subtypes. Sixty-seven miRNAs were significantly variant across the stroke subtypes. A subset of
exmiRNAs differed between haemorrhagic and ischaemic strokes, and LASSO analysis could
distinguish SAH from the other subtypes with an accuracy of 0.972 ± 0.002. Further analyses
predicted 25 miRNA classifiers that stratify IPH from ischaemic stroke with an accuracy of 0.811 ±
0.004 and distinguish haemorrhagic from ischaemic stroke with an accuracy of 0.813 ± 0.003.
Blood-based, ex-miRNAs have predictive value, and could be capable of distinguishing between
major stroke subtypes with refinement and validation. Such a biomarker could one day aid in the
triage of patients to expand the pool eligible for effective treatment.
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Introduction
Brain injury resulting from stroke is the leading cause
of morbidity in the USA and despite significant efforts
the development of neuroprotectants against stroke has
largely failed [1]. The only efficacious treatment for
ischaemic stroke is revascularization using clot-
busting agents such as tissue plasminogen activator
(tPA) [2,3], or endovascular mechanical thrombectomy
for patients with proximal large vessel occlusions [4–6].
Haemorrhagic stroke represents a subset of stroke cases
(~15%), yet can greatly confound stroke care as it is an
absolute contraindication for the administration of
chemical thrombolytics. The time required for diagno-
sis, triage and workup often results in delay in the
administration of tPA, or missing the therapeutic
window of an efficacious treatment altogether. While
medical imaging remains the gold-standard for stroke
diagnosis and management and these modalities are
largely accurate and effective; there remain inherent
limitations of these techniques around cost, length of
procedure, varied interpretation, challenges to imaging
certain brain regions (e.g. cerebellum and brainstem)
and most importantly the lack of availability in pre-
hospital settings [7]. In theory, a blood-based biomar-
ker that could rapidly discriminate between stroke
subtypes would be clinically valuable, and open the
future development of a point-of-care (POC) tool,
broadening access to effective therapeutics.
More than 10 years ago, it was recognized that RNAs
were contained within and could be shuttled between
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cells in extracellular vesicles, such as exosomes [8,9].
Extracellular RNAs (ex-RNAs) are typically carried
within vesicles or associated with RNA-binding proteins
or lipoproteins [10,11]. After discovery of RNA within
extracellular vesicles, the detection and expression of
these circulating RNA species were correlated with
different disease subtypes as well as disease progression
[12–14]. These ex-RNAs can be taken up by cells, func-
tionally regulate cellular processes and impact tissue
microenvironments[9,15]. The detection of miRNAs in
circulation has been associated with a host of CNS dis-
eases including neurogenerative diseases and brain can-
cer, making them attractive biomarkers for inaccessible
tissues and disease regions [16]. The abundance and
stability of circulating miRNAs, due to inherent structure
and packaging within vesicles, makes them even more
ideal candidates for biomarker discovery and develop-
ment. Our lab showed in a recent study of Alzheimer’s
and Parkinson’s disease patients, detectable ex-miRNA
changes in blood were found to be associated with disease
pathology [17]. Extracellular RNA expression levels can
change rapidly and have enough discriminative power to
act as sensitive biomarkers in a short time period.
There have been a number of studies to examine
differentially expressed miRNAs associated with intra-
cerebral haemorrhage or ischaemic stroke in blood
samples, using microarrays or qRT-PCR [18–23], or
sequencing [24,25]. Most studies were restricted to the
probes used for arrays or qRT-PCR-based assess-
ments, compared stroke to control, lacked classifica-
tion accuracy and used small patient cohorts. Both
animal and human studies have identified specific
miRNAs associated with ischaemic stroke [26].
Leung et al. showed that miR-124-3p was elevated in
haemorrhagic strokes compared to ischaemia [21].
Not only are miRNAs being used in diagnostic set-
tings, but also being explored as therapeutic targets. In
animal models, miRNAs associated with ischaemic
stroke are being targeted by therapeutic antagomirs
[27]. To date, no studies have employed next-
generation sequencing to comprehensively profile
miRNAs expressed in extracellular vesicles across
clinically relevant stroke subtypes to provide improved
molecular classifiers.
Herein we demonstrate the efficacy of plasma-
derived ex-miRNAs to serve as potential biomarkers
that allow for differentiation between major stroke
subtypes; intraparenchymal haemorrhage (IPH), subar-
achnoid haemorrhage (SAH) and ischaemic stroke.
These data serve as an initial comparison of these
stroke types, as well as a miRNA catalogue collected
from extracellular vesicles for future studies involving
these stroke subtypes.
Methods
Anonymized data and materials have been made
publicly available at the NCATS Extracellular
RNA Communications Consortium’s exRNA Atlas
(exRNA-atlas.org).
Patient sample collection
This study was approved by the institutional review
boards of St. Joseph’s Hospital and Medical Centre
(13BN094) and WIRB (#20120512). All patients or
their surrogates provided written informed consent
for participation in this study. Some study subjects
did not consent to providing the raw genetic informa-
tion in a public database. All aggregated sequencing
data, including counts for individual RNAs, can be
found at accession #EXR-KJENS10lPClY-AN (exrna-
atlas.org). All procedures followed were in accordance
with institutional guidelines.
All patients were evaluated by a neurosurgeon,
a neurologist, or both, and underwent complete neu-
rological examination (including assignment of the
National Institute of Health Stroke Scale score, intra-
cerebral haemorrhage score, Hunt and Hess and Fisher
scores), vascular imaging (using computed tomo-
graphic angiography) and magnetic resonance imaging
studies with diffusion-weighted sequences. All imaging
studies were evaluated by an independent neuro-
radiologist to characterize stroke subtypes as ischaemic,
SAH or spontaneous IPH. Patient characteristics are
provided in Table 1. Basic demographic data, as well as
information on participants’ current medications,
laboratory tests, family, social and medical and surgical
histories were collected. Daily physical examinations
were conducted and standard-of-care followed for all
subjects.
Blood (6-8 ml) was collected in EDTA tubes as recom-
mended by MISEV [28,29] from subjects with ischaemic
and haemorrhagic strokes (21 ischaemic strokes, 17
aneurysmal SAH and 19 spontaneous IPHs without
underlying vascular malformation) upon admission and
within 24 h of last known normal. Blood samples were
processed within 4 h of collection, spun for 10 min at 706
rcf at 4°C in an eppendorf 5804 R centrifuge using an
A-4-44 rotor to remove cells and debris. The supernatant
Table 1. Clinical characteristics across stroke subtypes.
n
Avg.
Age
Male:
Female
%
Caucasian
%
Smoker
%
Hypertensive
Ischaemic stroke 21 66 48:52 86 14 62
SAH 17 58 24:76 94 n/a n/a
IPH 19 65 58:42 84 16 79
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(plasma) was collected, and stored in 1 mL aliquots at –
80°C for RNA isolation and sequencing.
Extracellular vesicle collection and RNA isolation
Once all samples were collected, they were processed
simultaneously to eliminate batch effect variability due
to sample preparation and sequencing. Extracellular
vesicles were isolated from the plasma samples using
the exoRNeasy Serum/Plasma kit from Qiagen, which
has been shown to have high yield and reproducibility
[30,31]. A total of 10 ng of isolated RNA was prepared
for sequencing using the Illumina TruSeq Kit [32,33].
We followed the protocol in the Qiagen exoRNeasy
Serum/Plasma kit (Cat No./ID: 77044) to capture extra-
cellular vesicles on an affinity membrane, and then to
lyse the vesicles and isolate the extracellular RNA.
Briefly, 1 mL plasma samples were thawed at room
temperature and centrifuged at 3000 ×g for 5 min at 4°
C to remove debris. Samples were then applied to the
column following the manufacturer instructions.
RNA quantification
RNA was quantified in triplicate using Quant-iT
Ribogreen RNA Assay kit, Low-Range protocol
(R11490; ThermoFisher). A total of 10 ng of RNA
from each sample was used for small RNA library
preparation for sequencing.
Library preparation and sequencing
Library construction for sequencing was performed
as previously described [17,33]. Briefly, we used the
TruSeq small RNA sample preparation kit (RS-200-
0048; Illumina) with half the reaction volume and
reagents. RNA adaptors (3′ and 5ʹ) are specifically
ligated to small RNAs, and the resulting construct is
reverse transcribed. The construct is then enriched
by PCR (16 cycles) during which a unique barcode
was added to the sequence. The libraries were then
run on a 6% TBE Gel for 55 min at 140 V and the
product between 140 to 160 bp were excised from
the gels. These gel pieces were fractured into smaller
pieces and allowed to incubate on a rotator overnight
in water. An ethanol precipitation was performed to
precipitate the RNA and the resulting pellet of RNA
was resuspended in 11 ul of ultra-pure water.
Samples were quantified with the Agilent High
Sensitivity DNA Kit (5067–4626; Agilent). The peak
for the sample was integrated from 120 bp to 160 bp
to get the pMolarity. Samples with similar pMolarity
were grouped on the same lane and pooled together
to create a total of 8 unique pools containing 15
samples with different barcodes. These pools were
then quantified with the Agilent High Sensitivity
DNA Kit to get the final pMolarity for the pool.
The pools were then denatured and clustered on
a single read Illumina V3 flowcell (GD-401-3001;
Illumina). Illumina HiSeq 2500 next-generation
sequencing platform was used for all sequencing
experiments. All samples were sequenced to approxi-
mately the same depth/number of reads so that
quantitative comparisons can be made between
samples.
RNA-sequencing data analysis
The raw sequence image files from the Illumina
HiSeq in the form of .bcl were converted to the
fastq format using bcltofastq v. 2.19.1.403 and
checked for quality to ensure the quality scores did
not deteriorate at the read ends. The TruSeq adapters
from the 3′ end were clipped using cutadapt v.1.14.
Reads shorter than 15 nts were discarded and after
adapter trimming, the 3′ bases below a quality score
of 30 were also trimmed.
The reads are first mapped to a library of UniVec
contaminants, a collection of common vector, adapter,
linker and PCR primer sequences collated by the NCBI.
They are then mapped to human rRNA sequences
obtained from NCBI. The reads are mapped to the
rRNA and UniVec sequences using Bowtie2, reads
that map are removed from the analysis. The alignment
to the human genome and transcriptome takes place in
two stages. First, the rRNA and UniVec free reads are
mapped to the human genome (hg19) using STAR. The
reads that map to the genome are then mapped to the
human transcriptome. The reads that are not mapped
to the human genome are also mapped to the human
transcriptome. The library for the human transcrip-
tome was built by concatenating miRNAs and hairpins
from miRBase 21, tRNAs from gtRNAdb, piRNAs
from piRBase v1.0, protein-coding, non-coding and
other RNA sequences (such as antisense and pseudo-
genes) from ENSEMBL 75. The STAR alignment was
performed end-to-end with no mismatch allowed while
mapping and each read is allowed to multimap to at
most 40 RNA annotations.
Differential expression analysis
Differential expression was conducted using the DESeq2
package (version 1.20.0) in R (version 3.5.0) for allmiRNAs
that had expression levels >25 read counts in at least 50% of
samples in one of the groups [34]. The raw read counts for
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the samples were normalized with miRNA raw counts
using the median ratio method (default in DESeq2). The
top 20most significant differentially expressed ex-miRNAs
(by Benjamini-Hochberg adjusted p-value < 0.05) are
reported in the paper, the full table can be found as
Supplemental Table 1.
Classification analysis by L1-penalized regression
analysis (LASSO)
Lasso is a regularized linear model with L1-penalty to
control the complexity of the model, thus reducing the
risk of over-fitting the training data [35]. Lasso analysis
was performed using the normalized counts for miRNA
from DESeq2. Following differential expression analysis,
miRNAs with unadjusted p-values < 0.05 between sam-
ple groups (see above) were used in the glmnet package
(version 2.0.16) in R. A series of loops were implemen-
ted to (1) identify the optimal lamda value for lasso
model, (2) select the best lasso model and (3) estimate
performance metrics (for example, prediction accuracy
and AUC) for the selected model (Supplemental
Figure 1). In the first loop, we performed a series of
1000 iterations of cv.glmnet using random 80/20 train-
ing/test set splits. For each iteration the predict() func-
tion was used to calculate the accuracy for predicting the
test set and the lambda.min that corresponded to the
iteration with the highest accuracy, and was subse-
quently selected as the optimal lambda value for our
model. In the second loop, we performed a series of
1000 iterations of glmnet using random 80/20 training/
test set splits, but with a constant lambda, to determine
our best lasso model (the miRNAs found to be most
important in the iterations with the best predictive
value). The iteration with the highest accuracy was
called our best lasso model and the ex-miRNA feature
set corresponding to this model was selected for classi-
fication. In the third and the last loop, we performed
a final series of 1000 iterations of glmnet using random
80/20 training/test set splits, but kept the lambda and
miRNA feature set constant. This allowed average accu-
racy to be calculated from the average prediction accu-
racy of the test sets of the 1000 iterations, as the samples
contained in the training/test sets were randomly
selected. AUCs were determined from cv.glmnet()
using type.measure = ”auc” using the best lasso model.
Results
We collected samples from subjects suffering from
haemorrhagic stroke SAH (n = 17) or IPH (n = 19)
or ischaemic stroke (stroke, n = 21). Samples were
collected at the time of admission to the emergency
room. Samples were processed to plasma within 4 h of
the event and stored for future evaluation. Clinical
characteristics by stroke subtype can be found in
Table 1. While age did not statistically differ between
groups, the SAH subgroup consisted of ~75% female,
consistent with published reports of the more common
occurrence of SAH in females [36], whereas the other
stroke subtypes were close to a 50:50 male to female
ratio.
Several papers have already examined miRNAs asso-
ciated with stroke [19], and in this work we focused on
the discriminative power of ex-miRNA derived from
extracellular vesicles with specific stroke subtypes. There
are many ways in which we could isolate exRNA from
our samples. For these clinical samples, our goal was to
identify a robust and reproducible miRNA signal that
could have potential diagnostic value. We chose to isolate
exRNA from plasma samples using the Qiagen
exoRNeasy kit. This kit uses a membrane-affinity capture
for extracellular vesicle isolation first, and then uses phe-
nol/guanidine-based lysis and silica-membrane based
RNA purification [37].We chose to use this kit for several
reasons: (1) the first CLIA-validated extracellular vesicle-
based liquid biopsy test, ExoDx™ Lung (ALK), uses
exoRNeasy for RNA isolation from plasma, (2) in
a recent large multi-site assessment of ex-RNA isolation
methods in plasma [31], investigators found that the
exoRNeasy kit had the highest reproducibility in repli-
cates across multiple labs, suggesting that the technical
protocol is easily replicated and (3) in a study testing
several different extracellular vesicle isolation kits on
serum samples, they also reported the highest and most
uniform yield to come from the exoRNeasy kit [38].
Reproducible results with low variability were important
criteria for us to consider in our sample isolations, there-
fore, we also compared data from the exoRNeasy kit to
cell-free RNA isolations in our samples (Figure 1). We
compared the sequencing results from plasma samples
isolated using the exoRNeasy kit and using cell-free total
RNA with miRVana. In total, 20 plasma samples from
subjects with a SAH were used for the testing; 10 plasma
samples were isolated using the exoRNeasy kit and 10
plasma samples were isolated using cell-free total RNA
with miRVana. Previous experiments comparing cell-free
RNA isolation methods in our laboratory found that
miRVana provided us with high yield RNA isolations
from biofluids [39,40].
We found that when comparing the sequencing
results from total cell-free RNA to RNA isolated
using exoRNeasy for these 20 samples, there was an
increased number of miRNA detected (Figure 1(a))
and a reduced coefficient of variation of detected
miRNAs across samples isolated by exoRNeasy
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(Figure 1(b)). The exoRNeasy kit is currently used in
clinical testing, was found to be less variable across
multiple users and sites in other studies, and had less
variability and yielded a higher diversity of miRNA in
our samples, we proceeded with using this kit for our
plasma isolations.
The total usable reads (defined as reads mapping to
the transcriptome) were as follows across the groups:
ischaemic stroke (12,219,438 median, 9,747,058 IQR),
SAH (8,214,214 median, 5,806,412 IQR), and IPH
(9,438,557 median, 3,779,541 IQR). Supplemental
Table 1 shows a more detailed sequencing metrics per
stroke subtype and Supplemental Figure 2 shows the
range of small RNA lengths detected in the study. Ex-
miRNAs were included for further analyses if expressed
at more than 25 counts in at least 50% of samples of
any stroke subgroup. A total of 243 miRNAs were
detected at this stringent cut-off, with 214, 207, and
240 miRNAs detected in IPH, SAH and ischaemic
stroke, respectively.
We first identified differentially expressed ex-
miRNAs between each of the stroke types using the
Likelihood Ratio Test [34]. In Figure 2, we show the
top 25 miRNAs by smallest adjusted p-value that differ
between the three stroke groups. A total of 67 miRNAs
were found to be significantly different across the
stroke subtypes, and the full list can be found in
Supplemental Table 2.
In the 25 miRNAs with the largest fold change, SAH
tended to be the most divergent subgroup. The clinical
presentation of SAH is distinct from ischaemic stroke
and IPH, which more often have lateralizing signs
upon presentation.We therefore sought to identify ex-
miRNAs that best distinguished SAH from IPH and
ischaemic strokes combined, as both the phenotype
and data from Figure 2 suggested a measurable differ-
ence. Figure 3(a) depicts the 20 miRNAs (16 of which
remain statistically significant with multiple compar-
ison adjustment) that most distinguish SAH from the
other two stroke subtypes combined (IPH and ischae-
mic stroke) by lowest p-value. The full list of miRNAs
differentially expressed between SAH and IPH +
ischaemic stroke can be found in Supplemental Table
3. Employing the differentially expressed miRNAs,
LASSO analysis predicted a 25-miRNA classifier with
an AUC 0.927 ± 0.009 (standard error of the mean)
and accuracy of 0.972 ± 0.002 (Figure 3(b)) for dis-
criminating SAH from the other stroke subtypes. We
also determined the ex-miRNAs that best distin-
guished SAH from IPH (Supplemental Table 4) and
ischaemic stroke (Supplemental Table 5), respectively.
Supplemental Figure 3 depicts the 20 miRNAs that
best distinguish SAH from IPH (a total of 68 ex-
miRNAs were significant by adjusted p-value), and
Supplemental Figure 4 depicts the 20 miRNAs that
best distinguish SAH from ischaemic stroke (a total
of 52 ex-miRNAs were significant by adjusted
p-value). LASSO analyses predicted a
24-miRNA classifier with an AUC of 0.977 and accu-
racy of 0.944 (Supplemental Figure 3) and 21-miRNA
classifier (AUC of 0.895 and accuracy of 0.968
(Supplemental Figure 4) for discriminating SAH
Figure 1. Comparison of cell-free and exoRNeasy RNA isolation on miRNA detection and variability. The number of miRNA
detected is higher in the samples isolated using exoRNeasy (a) and the coefficient of variation for miRNAs across the 10 samples is
lower (b).
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from IPH and ischaemic stroke, respectively. We also
compared the miRNA data to LASSO results employ-
ing tRNA fragments or Gencode. The miRNA consis-
tently produced classifiers with better discriminative
power in this dataset (Supplemental Table 6), and thus
we focused on the miRNA.
As SAH is more common in women than men, we
sought to determine the impact of sex on ex-miRNA
expression. We compared men (n = 20) and women
(n = 20) in terms of ex-miRNAs. Only six ex-miRNAs
were significantly different by adjusted p-value
(Supplemental Table 7) between men and women,
Figure 2. Extracellular miRNAs are differentially expressed across three stroke subtypes. The top 25 ex-miRNAs by likelihood
ratio test are displayed. Only miRNAs with expression levels >25 counts in at least 50% of one subgroup were included in the
analysis. Each dot represents the mean count for the given miRNA in designated stroke subgroup (IPH-blue, SAH-
green and ischaemic stroke-red).
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and none of those were found differentially expressed
between SAH and any other stroke subtype.
We next sought to determine ex-miRNAs that could
distinguish between ischaemic and haemorrhagic strokes,
a critical distinction for therapeutic decision-making [3].
The top 20 differential ex-miRNAs (Figure 4(a)) by low-
est p-value between ischaemic stroke patients and those
with either SAH or IPH were determined. The full list of
differential miRNAs can be found in Supplemental
Table 8. Again, employing those ex-miRNAs found to
be differentially expressed between the ischaemic and
haemorrhagic stroke patients, LASSO analysis deter-
mined the best classifier to distinguish the groups.
Figure 4(b) shows a heat map with a 13 ex-miRNA
classifier, determined by LASSO, that distinguishes
ischaemic from haemorrhagic stroke with an AUC
0.752 ± 0.003 and accuracy of 0.813 ± 0.003. Thus,
while only one ex-miRNA in this comparison was sig-
nificant after adjusting for multiple comparisons, the
LASSO analysis still identified a classifier with better
than 80% accuracy.
An unmet clinical need is the ability to accurately
distinguish whether a stroke is IPH or ischaemic due to
the difference in therapeutic options. As such, we com-
pared those ex-miRNAs significantly different between
these stroke subgroups. Figure 5(a) shows the top 20
differentially expressed ex-miRNAs by smallest p-value.
The complete list of differential miRNAs between these
groups is shown in Supplemental Table 9. The differen-
tially expressed miRNAs between IPH and ischaemic
stroke were then used to determine an optimal classifier
with LASSO. The LASSO analysis determined a 21 ex-
miRNA classifier with an AUC of 0.824 ± 0.001 and
accuracy of 0.811 ± 0.004 (Figure 5(b)). Again, while
Figure 3. Ex-miRNAs can accurately distinguish SAH from other stroke subgroups. (a) The top 20 miRNAs by lowest p-value
are shown in the dot-plots. Dots represent mean counts for the given miRNA per patient across the stroke subgroups. Statistical
significance was determined by DESeq 2 with Benjamini–Hochberg method employed to adjust for multiple comparisons. (b) The
heatmap depicts the ex-miRNAs selected by LASSO analysis with best discriminatory power. The graph below the heatmap displays
the direction of regulation of the miRNA selected by LASSO.
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individual miRNAs tended to lose statistical significance
post adjusting for multiple comparisons, a LASSO clas-
sifier discriminated the subtypes with 81% accuracy.
Discussion
The rapid and accurate diagnosis of stroke subtype
directly impacts the administration of effective thera-
peutics such as tPA and mechanical revascularization.
A major challenge in caring for patients suffering from
stroke is arriving at a timely and correct diagnosis of
ischaemic versus haemorrhagic stroke so that patients
with vascular occlusion may be revascularized. Despite
the accuracy of medical imaging to diagnose and man-
age stroke, limitations remain around cost, variability
in interpretation and a lack of access outside of hospi-
tals. While mobile stroke units and portable imaging
can improve time to diagnosis and therapeutic delivery,
these options are costly and impractical to date in rural
areas. As such, there is an unmet need to develop
biomarkers that could rapidly distinguish stroke sub-
types towards therapeutic decision-making.
In this work we demonstrate the potential utility of
extracellular miRNAs derived from extracellular vesi-
cles to distinguish between stroke subtypes. Differences
between ischaemic and haemorrhagic strokes can be
accurately depicted by ex-miRNAs, and difficult to
discern phenotypes such as ischaemic stroke versus
IPH can be stratified by a set of ex-miRNAs at an
AUC of 0.824 and accuracy of 0.811. However, this
level of sensitivity still requires improvement in order
to be clinically actionable. We need a larger cohort of
subjects from which we will continue to sequence the
RNA cargo, to discover and validate miRNA, as well as
Figure 4. Ex-miRNAs can distinguish ischaemic from haemorrhagic stroke types. (a) The top 20 miRNAs by lowest p-value are
shown in the dot-plots. Dots represent mean counts for the given miRNA per patient across the stroke subgroups. Statistical
significance was determined by DESeq2 with Benjamini–Hochberg method employed to adjust for multiple comparisons. (b) The
heatmap depicts the ex-miRNAs selected by LASSO analysis with best discriminatory power. The graph below the heatmap displays
the direction of regulation of the miRNA selected by LASSO.
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other RNA fragments and biotypes that may provide
additional detail and accuracy to the signal.
A number of miRNAs have been associated with
stokes and stroke subtypes [19]. Our analysis showed
elevated expression of miR-27b-3p in ischaemic stroke
compared to haemorrhagic stroke types. Cheng et al.
previously detected miR-27b-3p at elevated levels in
ischaemic stroke patients compared to controls [41].
miR-146b-5p has also been shown at higher levels in
ischaemic stroke patients compared to controls [42],
while we observed this miRNA elevated in ischaemic
stroke patients compare to the SAH subtype. While
several miRNAs detected in our study have been pre-
viously implicated with strokes our study determined
several miRNAs not previous identified in stroke
patients, and especially those capable of deciphering
specific stroke subtypes. The SAH subtype was dis-
cerned from other stroke subtypes by a subset of ex-
miRNAs with an AUC of 0.927 and accuracy of 0.972.
As SAH is phenotypically distinct from other stroke
subtypes, our data suggest a subset of circulating
miRNAs associated with this type of insult. Though
more difficult to distinguish, a classifier of ex-
miRNAs could distinguish IPH from ischaemic stroke,
a stratification with therapeutic significance. The abun-
dance and inherent stability of circulating miRNAs
make them ideal biomarkers in biofluids, such as
plasma, serum, cerebrospinal fluid and saliva [10].
One challenge of utilizing nucleic acids (including
miRNAs) in a POC therapeutic setting is detection in
small volumes without the use of time-intensive sequen-
cing platforms. We are not advocating NGS for patient
triage at this time, merely using it for classifier develop-
ment, which after validation could be pursued in a POC
test. New technologies are currently being developed that
are poised to make POC detection feasible. Using
Figure 5. Ex-miRNAs can distinguish IPH from ischaemic stroke. (a) The top 20 miRNAs by lowest p-value are shown in the dot-
plots. Dots represent mean counts for the given miRNA per patient across the stroke subgroups. Statistical significance was
determined by DESeq2 with Benjamini-Hochberg method employed to adjust for multiple comparisons. (b) The heatmap depicts
the ex-miRNAs selected by LASSO analysis with best discriminatory power. The graph below the heatmap displays the direction of
regulation of the miRNA selected by LASSO.
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a power-free microfluidic device, Arata et al. detected 0.5
picomolar miRNA in 0.5 uL [43]. Alternative technolo-
gies in amplification, such as isothermal, paper-based or
nanobead-based [44], are all making the field use of
miRNAs as biomarkers a realistic endeavour.
Understanding those ex-miRNAs with the most discri-
minative power with regard to stroke subtypes and clin-
ical outcomes will propel these innovative techniques to
clinical utility.
We recognize some challenges inherent to this
study. First, the clinical sample size is small per stroke
subgroup. We also recognize that the timing of blood
collection in relation to disease progression can intro-
duce variability, variance we are evaluating in studies
where progressive blood samples are taken from the
same stroke patient. We aim to validate these findings
in larger cohorts across institutions. Without external
validation and using a small number of ex-miRNA
features to input into LASSO, we recognize that over-
fitting is a possibility. We further recognize that the
miRNAs detected in circulation are only a portion of
the small RNA cargo in extracellular vesicles that can
be detected by next-generation sequencing. Though,
beyond the scope of this manuscript, we aim to deter-
mine the full RNA cargo detectable in circulation.
Recently discovered RNA species such as isomiRs,
piRNA, tRNA fragments, lncRNA, rRNA and Y RNA
fragments have been detected in biofluids and may also
be used in the stratification of disease subtypes [45].
We also purposefully did not validate these findings by
q-RT-PCR as the sensitivity of next-generation sequen-
cing is often not validated by probe-based techniques,
as demonstrated by Beck et al. with regard to variant
calling and Sanger sequencing [46]. While we chose
expression thresholds that were conservative (>25
counts), RNAs with low abundance are more difficult
to validate across platforms. We, and others, have
demonstrated that small RNAs with high expression
are reliably validated on several platforms, but as the
expression levels get lower, each validation platform
demonstrated weaknesses [33,47]. It still remains con-
troversial, what are the appropriate normalizing RNAs
for extracellular experiments [48]. We will continue to
identify and test validation tools for sequencing. Also,
we are unable to determine the cell of origin for the
EVs collected, or if the collection protocols impact EV
secretion from cell types, such as platelets.
This work demonstrates the potential of ex-miRNAs
derived from extracellular vesicles as biomarkers for
differentiating between major stroke subtypes. The uti-
lity of this class of biomarker to differentiate between
ischaemic and haemorrhagic stroke subtypes suggests
that they could be developed into a POC test that can
be administered in the field to assist with diagnosis and
patient triage. Further clinical testing of these panels
can enhance care of patients suffering from stroke.
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